Navigation Links
Onyx Pharmaceuticals Reports First Quarter 2011 Financial Results
Date:5/4/2011

)Net loss per share:Basic$
(0.78)$
(0.19)Diluted (4)$
(0.78)$
(0.19)Computation of diluted shares:Basic 63,00862,353Dilutive effect of options--Diluted (4)63,00862,353(1)  Includes employee stock-based compensation charges of:Research and development$
926$
912Selling, general, and administrative4,4294,030Total employee stock-based compensation$
5,355$
4,942(2)
Includes a $12.7 million non-cash expense related to the unamortized balance of funding provided to S*BIO in May 2010.

(3) Includes a $3.0 million impairment charge which reflects the reassessment of the fair value of Onyx's equity investment in S*BIO.

(4) Under the "if-converted" method, interest and issuance costs and potential common shares related to the Company's convertible senior notes were excluded in the computation of diluted per share amounts for the three months ended March 31, 2011 and 2010 because their effect would be anti-dilutive. ONYX PHARMACEUTICALS, INC.CALCULATION OF REVENUE FROM COLLABORATION AGREEMENT(In thousands, unaudited)Three Months EndedMarch 31, 20112010Nexavar product revenue, net (as recorded by Bayer)$ 235,467$ 214,361Nexavar revenue subject to profit sharing (as recorded by Bayer)$ 193,170$ 185,867Combined cost of goods sold, distribution, selling, general and administrative expenses74,01075,698Combined collaboration commercial profit$ 119,160$ 110,169Onyx's share of collaboration commercial profit$   59,580$   55,084Reimbursement of Onyx's shared marketing expenses4,6045,824Royalty revenue2,9611,995Revenue from collaboration agreement$   67,145$   62,903ONYX PHARMACEUTICALS, INC.RECONCILIATION OF GAAP TO NON-GAAP NET LOSS(In thousands, except per share amounts)(unaudited)Three Months EndedMarch 31, 20112010GAAP net loss$(49,162)$(12,044)Non-GAAP adjustments:Contingent consideration11,4953,448Employee stock-based compensation5,3554,942Imputed interest related to the conver
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... Belgium , Sept. 1, 2015 VolitionRx ... on developing blood-based diagnostic tests for a broad range of ... Executive Officer, Cameron Reynolds , is scheduled to attend ... is being held September 9-10, 2015 in Boston, ... on September 10. Wells Fargo Securities Research ...
(Date:9/1/2015)... , Sept. 1, 2015 Sargas ... Management (CCM) and Drug Adherence m Health applications ... automate the process of non face-to-face monitoring of ... this new release of our apps, doctors are ... services along with our ONCHIT certified Physician, Pharmacy ...
(Date:9/1/2015)... Sept. 1, 2015   Ivenix Inc. , ... management system, closed on a $42M round of ... Ventures. Cardinal Partners, CICA, Inc., Easterly Capital, Fidelity ... the round. This financing will support the company,s ... Leerink Partners LLC acted as the exclusive placement ...
Breaking Medicine Technology:VolitionRx to Attend 10th Annual Wells Fargo Healthcare Conference on September 9-10, 2015 2VolitionRx to Attend 10th Annual Wells Fargo Healthcare Conference on September 9-10, 2015 3VolitionRx to Attend 10th Annual Wells Fargo Healthcare Conference on September 9-10, 2015 4SPAC International's Drug Adherence and Chronic Care Management App Now available at Apple App and Google Play stores 2Ivenix Inc. Secures $42 Million in Funding 2Ivenix Inc. Secures $42 Million in Funding 3
... JERUSALEM , June 2, ... oral drug delivery systems, announced,today that its subsidiary Oramed Ltd. ... ("Laser Detect"), an Israeli company listed on,the Tel Aviv Stock ... Entera Bio Ltd. ("Entera"). Under the terms of the agreement, ...
... Questcor Pharmaceuticals, Inc . (Nasdaq: QCOR ) announced today that it ... June 10, 2010 at The Grand Hyatt Hotel in New York, ... will discuss the Company,s business strategy and historical financial performance at 11:30 ... , Attendance at ...
Cached Medicine Technology:Oramed Pharmaceuticals Forms Joint Venture - Launches Entera Bio Ltd. 2Oramed Pharmaceuticals Forms Joint Venture - Launches Entera Bio Ltd. 3Questcor to Present at the Jefferies 2010 Global Life Sciences Conference 2
(Date:9/1/2015)... Greifensee, Switzerland (PRWEB) , ... September 01, 2015 ... ... “Calibration and Qualification of Laboratory Instruments in accordance with GMP requirements“ , ... be presented on October 6th, 2015 at 11:00 EDT (15:00 GMT). , ...
(Date:9/1/2015)... , ... September 01, 2015 , ... Mercy Health (formerly ... devoted the 10th of its monthly Mercy Health: Helping You Be Well videos to ... in seven men. , In a concise video on Mercy Health’s YouTube channel, ...
(Date:9/1/2015)... , ... September 01, 2015 , ... ... 9, 2015 from 5:00 to 8:00 pm at the Marriott Indianapolis Downtown, 350 ... with career opportunities will be attending from across the country. All specialties will ...
(Date:9/1/2015)... ... September 01, 2015 , ... Éminence Organic Skin Care ... VitaSkin™ Exfoliating Peels. This revolutionary collection of natural peel solutions complements the existing ... , Formulated with alpha hydroxy acids and natural active ingredients, these results-oriented ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... has established the MAP Recovery Network, the Premier Outcomes-Driven Provider Network. It ... rapidly-growing alliance is dedicated to the provision of quality addiction treatment and ...
Breaking Medicine News(10 mins):Health News:Live Webinar from Pharmaceutical Technology and METTLER TOLEDO on Calibration and Qualification of Laboratory Instruments 2Health News:New Mercy Health Video Explains Most-Common Cancer Found in Men 2Health News:PracticeMatch to Host Physician Career Fair at the Marriott Indianapolis Downtown on September 9, 2015 2Health News:PracticeMatch to Host Physician Career Fair at the Marriott Indianapolis Downtown on September 9, 2015 3Health News:PracticeMatch to Host Physician Career Fair at the Marriott Indianapolis Downtown on September 9, 2015 4Health News:Éminence Organic Skin Care Introduces Results-Oriented Exfoliating Peels for Every Skin Type 2Health News:Éminence Organic Skin Care Introduces Results-Oriented Exfoliating Peels for Every Skin Type 3Health News:MAP Health Management Launches the MAP Recovery Network 2
... or engineer? Sex hormones strongly influence people,s interests, ... according to psychologists. , "Our results provide strong ... characterized by working with things versus people," said ... with Sheri A. Berenbaum, professor of psychology and ...
... 1 (HealthDay News) -- The intensity of exercise, not the ... of living a longer life, a new study suggests. ... with high levels of cycling intensity lived 5.3 years longer, ... men with low intensity. Among female cyclists, those with ...
... IL A natural yellowing of the eye lens that absorbs ... of test volunteers, according to a,study in the September 1 issue ... discoloration worsened with age, so did the risk of insomnia. ... why sleep disorders become more frequent with increasing age," said Line ...
... hospitalization rates in adolescents and young adults aged 15 ... 2008 according to a study conducted by researchers at ... findings available today in Annals of Neurology , ... Child Neurology Society, report an increase in the prevalence ...
... the September issue of the Journal of the American ... in chest computed tomography (CT) scans. Chest CT is the ... the cause of clinical signs or symptoms of the chest, ... Regardless of the body region being scanned, dose ...
... , WEDNESDAY, Aug. 31 (HealthDay News) -- New research ... files could greatly improve care for diabetic patients by ... faster" at various kinds of medical clinics that had ... Cebul, a professor of medicine at Case Western Reserve ...
Cached Medicine News:Health News:Sex hormones impact career choices 2Health News:Aging eyes linked to sleepless nights, new study shows 2Health News:Increased prevalence of stroke hospitalizations seen in teens and young adults 2Health News:Electronic Medical Records Might Boost Diabetes Care 2Health News:Electronic Medical Records Might Boost Diabetes Care 3
... Chamber Lenses: The Bausch & Lomb PMMA Posterior ... for primary implantation for the visual correction of ... older where a cataractous lens has been removed ... to be placed in the ciliary sulcus or ...
... are manufactured using the highest ... CQ UV PMMA material is ... single piece lenses. Unioptic lens ... nonphaco and phaco styles. All ...
... STAARVISC II is a sterile nonpyrogenic, ... hyaluronate. STAARVISC II contains 12 mg/ml of ... daltons) sodium hyaluronate dissolved in physiological saline. ... the viscosity is 105,000 cps (105 Pa ...
... viscoelastic agent for the surgeon who performs ... Amvisc possesses sufficient viscosity for excellent chamber ... cohesive so that complete removal at the ... quickly accomplished. Amvisc is priced to compete ...
Medicine Products: